

RESOLUTION

On approval of the results of the public offering of additional shares to existing shareholders

Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020, and its amendments and supplements;

Pursuant to the Law on Securities No. 54/2019/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on November 26, 2019, and its amendments and supplements;

Pursuant to Decree No. 155/2020/ND-CP dated December 31, 2020 of the Government detailing and guiding the implementation of a number of articles of the Law on Securities, as amended and supplemented by Decree No. 245/2025/ND-CP dated September 11, 2025;

Pursuant to the Charter on organization and operation of Agimexpharm Pharmaceutical JSC;

Pursuant to the Resolution of the General Meeting of Shareholders No. 02/NQ-AGP.DHDCD dated August 25, 2025 of Agimexpharm Pharmaceutical Joint Stock Company adopted by written voting and Proposal No. 07/TT-AGP.DHDCD dated August 12, 2025 on approval of the plan for public offering of additional shares to existing shareholders;

Pursuant to the Certificate of Registration for public offering of additional shares issued by the State Securities Commission No. 419/GCN-UBCK dated November 12, 2025;

Pursuant to the Resolution of the Board of Directors No. 16/NQ-AGP.HDQT dated December 31, 2026 on approval of results of the exercise of subscription rights and plan for handling fractional shares and unsubscribed shares arising from the public offering of additional shares to existing shareholders;

Pursuant to the actual results of the offering;

Pursuant to the confirmation issued by the bank where the escrow account is opened regarding the proceeds collected from the offering;

Pursuant to the Minutes of the Meeting of the Board of Directors of Agimexpharm Pharmaceutical Joint Stock Company No. 01/BB-AGP.HDQT dated January 09, 2026.

HEREBY RESOLVES:

Article 1: To approve the results of the public offering of additional shares to existing shareholders of Agimexpharm Pharmaceutical Joint Stock Company (the "Company") in accordance with the Certificate of Registration for the public offering of additional shares No. 419/GCN-UBCK issued by the Chairman of the State Securities Commission of Vietnam on November 12, 2025, as follows:

Summary of the results of the public offering of additional shares to existing shareholders

1. Name of shares: Shares of Agimexpharm Pharmaceutical Joint Stock Company
2. Type of shares: Ordinary shares
3. Stock code: AGP
4. Offering price: VND 25,000/share
5. Number of shares registered for offering: 3,992,290 shares
6. Number of shares offered: 3,992,290 shares, equivalent to 100% of the total number of shares registered for offering, including:
 - Number of shares subscribed for and paid by shareholders/investors in the offering to existing shareholders up to December 25, 2025: 3,930,712 shares
 - Number of fractional shares arising from rounding down that were subscribed for and paid by other investors up to January 06, 2026: 344 shares
 - Number of unsubscribed shares due to existing shareholders' failure to register or pay for the subscription that were subscribed for and paid by other investors up to January 06, 2026: 61,234 shares.

7. Total proceeds: VND 99,807,250,000
8. Number of shares after the offering: 30,607,558 shares
9. Closing date of the offering: January 06, 2026
10. Expected share transfer date:
- For existing shareholders exercising their rights to purchase shares from December 4, 2025 to December 25, 2025, and investors allocated odd shares arising from rounding down: Q1/2026.
 - For investors allocated the remaining shares not fully subscribed due to existing shareholders' failure to register for or pay for the purchase: Q1/2027.
11. The balance of funds in the Company's escrow account, based on the Confirmation Letter issued by Vietnam Joint Stock Commercial Bank for Industry and Trade – An Giang Branch regarding the confirmation of the escrow account balance for the offering (as of January 8, 2026), is VND 99,943,840,567.
- The difference of VND 136,590,567 compared to the proceeds collected from the offering is attributable to the following reasons:

No.	Details of reasons	Amount (VND)
(1)	Balance prior to December 4, 2025 – the commencement date for share subscription registration and payment	(**) 136,50,488
	– Balance as of November 24, 2025	136,500,000
	– Interest accrued in the account (from November 24, 2025 to November 30, 2025)	4,488
(2)	Interest accrued in the account (up to December 31, 2025)	1,186,079
(3)	Transfer fee from the account of the Vietnam Securities Depository and Clearing Corporation (VSDC) to the Company's escrow account for receipt of share subscription proceeds	1,100,000
Total = (1) + (2) – (3)		136,590,567

(**) Note: As of November 24, 2025, there was one (01) shareholder who registered to exercise the subscription right and paid the share purchase amount ahead of the deadline specified in the Public Offering Announcement No. 06/TB-AGP dated November 13, 2025 of Agimexpharm Pharmaceutical Joint Stock Company, with a payment amount of VND 136,500,000. The interest accrued on this amount up to November 30, 2025 was VND 4,488.

Summary of expenses for the additional public offering of shares to existing shareholders of the Company: **VND 479,800,000**, including:

- Underwriting fee (if any): VND 0.
- Share distribution fee (if any): VND 0.
- Issuance advisory/consulting fee (inclusive of 10% VAT): VND 385,000,000.
- Fee for issuance of the certificate of public offering of shares: VND 5,000,000.
- Fee charged by the Vietnam Securities Depository and Clearing Corporation (VSDC) for fixing the list of shareholders entitled to exercise subscription rights (inclusive of 10% VAT): VND 7,700,000.
- Audit fee for expected charter capital (inclusive of 8% VAT): VND 64,800,000.
- Transfer fee from the VSDC account to the Company's escrow account for receipt of share subscription proceeds (inclusive of 10% VAT): VND 1,100,000.
- Newspaper publication costs for disclosure of information related to the offering (inclusive of 8% VAT): VND 16,200,000.
- Other expenses: VND 0.

Net proceeds from the offering: **VND 99,327,450,000**.

Article 2: To authorize the General Director to direct and execute the signing of all documents, dossiers and relevant materials in accordance with applicable laws.

Article 3: Members of the Board of Directors, the Board of General Directors and relevant individuals of Agimexpharm Pharmaceutical Joint Stock Company shall be responsible for the implementation of this Resolution.

Article 4: This Resolution shall take effect from the date of signing./.

Recipients:

- As stated in Articles 2 and 3;
- Board of Directors, Board of Supervisors;
- Archived: BOD Secretariat.

**ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRPERSON**



PHARM. PHAM THI BICH THUY



